Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06075667 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06075667: Active Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT06075667 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 150 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06075667, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits. Participants who have completed the primary 72-week GPHP study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
Ohio
- Aventiv Research Inc - Columbus
- PriMED Clinical Research - Dayton
Ontario
- The Wharton Medical Clinic Clinical Trials Inc - Hamilton
- The Hospital for Sick Children - Toronto
Other
- Nemocnice Jihlava - Jihlava
- Fakultni nemocnice Kralovske Vinohrady - Prague
Georgia
- CenExel iResearch, LLC - Decatur
Idaho
- Solaris Clinical Research - Meridian
Kansas
- Cotton O'Neil Diabetes & Endocrinology - Topeka
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Maryland
- Barry J. Reiner, MD, LLC - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2029-07 |
| Phase | Phase 3 |
What the registry record for NCT06075667 still lists
NCT06075667 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06075667 names 20 study sites across 17 states, led by Ohio, Ontario, Other.
Frequently Asked Questions
What is clinical trial NCT06075667 about?
NCT06075667 is a clinical study titled "A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities". The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits. Participants who have completed the primary 7...
What is the current status of trial NCT06075667?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2023-10-16. Estimated completion is 2029-07.
What conditions does trial NCT06075667 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06075667?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06075667?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06075667 being conducted?
This trial has 20 study locations across Georgia, Idaho, Kansas, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06075667's enrollment target sits among peer trials
150 370th of 1053 higher than 668 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI